Oxybutynin: An overview of the available formulations

Therapeutics and Clinical Risk Management

Volumn 2, Issue 1, 2006, Pages 19-24

  McCrery, Rebecca J ^a   Appell, Rodney A ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

Antimuscarinic; Detrusor overactivity; Overactive bladder; Urinary incontinence

Indexed keywords

ACETYLCHOLINE; DARIFENACIN; ITRACONAZOLE; MUSCARINIC RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; ORAL CONTRACEPTIVE AGENT; OXYBUTYNIN; PLACEBO; PROPANTHELINE BROMIDE; PROPIVERINE; TOLTERODINE; TROSPIUM CHLORIDE;

BLURRED VISION; CLINICAL TRIAL; CONSTIPATION; DETRUSOR DYSSYNERGIA; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG MARKETING; DRUG METABOLISM; DRUG RELEASE; DRUG TOLERABILITY; ERYTHEMA; EYE TOXICITY; FIRST PASS EFFECT; HUMAN; MICTURITION DISORDER; NAUSEA; NERVOUSNESS; OVERACTIVE BLADDER; PATIENT COMPLIANCE; PHARMACOLOGICAL BLOCKING; PRURITUS; REVIEW; SIDE EFFECT; SOMNOLENCE; XEROSTOMIA;

EID: 33745470104     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Abrams P, Freeman R, Anderstrom C, et al. 1998. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol, 81:801-10.
2. Abrams P, Cardozo L, Fall M, et al. 2002. The standardisation of terminology of lower urinary tract function: report from the standardization sub-committee of the International Continence Society. Neurourol Urodyn, 21:167-78.
3. Altan-Yaycioglu R, Yaycioglu O, Aydin Akova Y, et al. 2005. Ocular side-effects of tolterodine and oxybutynin, a single-blind prospective randomized trial. Br J Clin Pharmacol, 59:588-92.
4. [ALZA] Alza Corporation. Product monograph: Ditropan XL® (oxybutynin extended-release tablets) [online]. Accessed 26 Aug 2005. URL: http:// www.ditropanxl.com.
5. Anderson RU, Mobley BB, Saltzstein D, et al. 1999. Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. J Urol, 161:1809-12.
6. Appell RA, Chancellor MB, Zobrist RH, et al. 2003. Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects. Mayo Clin Proc, 78:696-702.
7. Appell RA, Diokno A, Antoci J, et al. 2000. One-year, prospective, open-label trial of controlled-release oxybutynin for overactive bladder in a community-based population [abstract]. Neurourol Urodyn, 19:526.
8. Appell RA, Sand P, Dmochowski R, et al. 2001. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartate in the treatment of overactive bladder: results of the OBJECT trial. Mayo Clin Proc, 76:358-63.
9. Barkin J, Corcos J, Radomski S, et al. 2004. A randomized, double-blind, parallel-group comparison of controlled- and immediate-release oxybutynin chloride in urge urinary incontinence. Clin Ther, 26: 1026-36.
10. Birns J, Lukkari E, Malone-Lee JG, et al. 2000. A randomized controlled trial comparing the efficacy of controlled-release oxybutynin tablets (10 mg once daily) with conventional oxybutynin tablets (5 mg twice daily) in patients whose symptoms were stabilized on 5 mg twice daily of oxybutynin. BJU Int, 85:793-8.
11. Chancellor MB, Appell RA, Sathyan G, et al. 2001. A comparison of the effects on saliva output of oxybutynin chloride and tolterodine tartate. Clin Ther, 23:753-60.
12. Chapple CR, Abrams P. 2005. Comparison of darifenacin and oxybutynin in patients with overactive bladder: assessment of ambulatory urodynamics and impact on salivary flow. Bur Urol, 48:102-9.
13. Chu FM, Dmochowski RR, Lama DJ, et al. 2005. Extended-release formulations of oxybutynin and tolterodine exhibit similar central nervous system tolerability profiles: a subanalysis of data from the OPERA trial. Am J Obstet Gynecol, 192:1849-54.
14. Comer AM, Goa KL. 2000. Extended-release oxybutynin. Drugs Aging, 16:149-55.
15. Davila GW, Daugherty CA, Sanders SW, et al. 2001. A short-term multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. J Urol, 166:140-5.
16. Diokno AC, Appell RA, Sand PK, et al. 2003. Prospective, randomized double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc, 78:687-95.
17. Dmochowski R, Appell RA. 2003. Advancements in minimally invasive treatments for female stress urinary incontinence. Curr Urol Rep, 4:350-5.
18. Dmochowski RR, Davila GW, Zinner, et al. 2002. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J Urol, 168:580-6.
19. Dmochowski RR, Sand PK, Zinner NR, et al. 2003. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology, 62:237-42.
20. Douchamps J, Derenne F, Stockis A, et al. 1988. The pharmacokinetics of oxybutynin in man. Eur J Clin Pharmacol, 35:515-20.
21. Drutz HP, Appell RA, Gleason D, et al. 1999. Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct, 10: 283-9.
22. Echols K, Verma U, Policaro F, et al. 2000. Idiopathic bladder hyperactivity and ditropan: an efficacy and compliance issue [abstract]. Obstet Gynecol, 95:S24.
23. Guay DRP. 2003. Clinical pharmacokinetics of drugs used to treat urge incontinence. Clin Phamocokinet, 42:1243-85.
24. Gupta SK, Sathyan G. 1999. Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin. J Clin Pharmacol, 39:289-96.
25. Halaska M, Ralph G, Wiedemann A, et al. 2003. Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. World J Urol, 20:392-9.
26. Homma Y, Paick JS, Lee JG, et al. 2003. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial. BJU Int, 92:741-7.
27. Hu T, Wagner TH, Bentkover JD, et al. 2004. Costs of urinary incontinence and overactive bladder in the United States: a comparative study. Urology, 63:461-5.
28. Kachur JF, Peterson JS, Carter JP, et al. 1988. R and S enantiomers of oxybutynin: pharmacological effects in guinea pig bladder and intestine. J Pharmacol Exp Ther, 247:867-72.
29. Kelleher CJ, Cardozo LD, Khullar V, et al. 1997. A new questionnaire to assess the quality of life of urinary incontinent women. Br J Obstet Gynaecol, 104:1374-9.
30. Lai HH, Boone TB, Appell RA. 2002. Pharmacologic treatment for detrusor overactivity. Curr Urol Rep, 3:365-72.
31. Lawrence M, Guay, Benson SR, et al. 2000. Immediate-release oxybutynin versus tolterodine in detrusor overactivity: a population analysis. Pharmacotherapy, 20:470-5.
32. Lehtoranta K, Tainio H, Lukkari-Lax E, et al. 2002. Pharmacokinetics, efficacy, and safety of intravesical formulation of oxybutynin in patients with detrusor overactivity. Scand J Urol Nephrol, 36:18-24.
33. Lukkari E, Juhakoski A, Aranko K, et al. 1997. Itraconazole moderately increases serum concentrations of oxybutynin but does not affect those of the active metabolite. Eur J Clin Pharmacol, 52:403-6.
34. Madersbacher H, Stohrer M, Richter R, et al. 1995. Trospium chloride versus oxybutynin: a randomized, double-blind, multicentre trial in the treatment of detrusor hyperreflexia. Br J Urol, 75:452-6.
35. Madersbacher H, Halaska M, Voigt R, et al. 1999. A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. BJU Int, 84:646-51.
36. Nilvebrant L, Andersson KE, Gillberg PG, et al. 1997. Tolterodine - a new bladder-selective antimuscarinic agent. Eur J Pharmacol, 327:195-207.
37. Noronha-Blob L, Kachur JF. 1991. Enantiomers of oxybutynin: in vitro pharmacological characterization at M1, M2, and M3 muscarinic receptors and in vivo effects on urinary bladder contraction, mydriasis and salivary secretion in guinea pigs. J Pharmacol Exp Ther, 256: 562-7.
38. [OMNP] Ortho-McNeil Pharmaceutical, Inc. Product monograph: Ditropan® (oxybutynin chloride). [online]. Accessed 26 Aug 2005. URL: http:// www.orthomcneil.com.
39. Preik M, Abrecht D, O'Connell M, et al. 2004. Effect of controlled-release delivery on the pharmacokinetics of oxybutynin at different dosages: severity-dependent treatment of the overactive bladder. BJU Int, 94:821-7.
40. Riva D, Casolati E. 1984. Oxybutynin chloride in the treatment of female idiopathic bladder instability. Results from double blind treatment. Clin Exp Obstet Gynecol, 11:27-42.
41. Rovner ES. 2004. Trospium chloride in the management of overactive bladder. Drugs, 64:2433-46.
42. Sathyan G, Chancellor MB, Gupta SK. 2001. Effect of OROS® controlled-release delivery on the pharmacokinetics and pharmacodynamics of oxybutynin chloride. Br J Clin Pharmacol, 52:409-17.
43. Scheife R, Takeda M. 2005. Central nervous system safety of anticholinergic drugs for the treatment of overactive bladder in the elderly. Clin Ther, 27:144-53.
44. Siddiqui MAA, Perry CM, Scott LJ. 2004. Oxybutynin extended-release, a review of its use in the management of overactive bladder. Drugs, 64:885-912.
45. Stewart K, McGhan WF, Offerdahl T, et al. 2002. Overactive bladder patients and the role of the pharmacist. J Am Pharm Assoc, 42: 469-76.
46. Stewart WF, Van Rooyen JB, Cundiff GW, et al. 2003. Prevalence and burden of overactive bladder in the United States. World J Urol, 20:327-36.
47. Tapp AJ, Cardozo LD, Versi E, et al. 1990. The treatment of detrusor instability in post-menopausal women with oxybutynin chloride: a double blind placebo controlled study. Br J Obstet Gynaecol, 97: 521-6.
48. Thuroff JW, Bunke B, Ebner A, et al. 1991. Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. J Urol, 145:813-16.
49. Todorova A, Vonderheid-Guth, B, Dimpfel W. 2001. Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. J Clin Pharmacol, 41:636-44.
50. van der Vaart CH, De Leeuw JRJ, Roovers JPWR, et al. 2002. The effect of urinary incontinence and overactive bladder symptoms on quality of life in young women. BJU Int, 90:544-9.
51. Versi E, Appell RA, Mobley D, et al. 2000. Dry mouth with convencional and controlled-release oxybutynin in urinary incontinence. Obstet Gynecol, 95:718-21.
52. Waldeck K, Larsson B, Andersson KE. 1997. Comparison of oxybutynin and its active metabolite, N-desethyl-oxybutynin, in the human detrusor and parotid gland. J Urol, 157:1093-7.
53. [WP] Watson Pharma, Inc. Product monograph: Oxytrol™ (oxybutynin transdermal system) [online]. Accessed 26 Aug 2005. URL: http:// www.oxytrol.com.
54. Yarker YE, Goa KL, Fitton A. 1995. Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging, 6:243-62.
55. Zobrist RH, Schmid B, Feick A, et al. 2001. Pharmacokinefics of the R- and S-enantiomers of oxybutynin and N-desethyloxybutynin following oral and transdermal administration of the racemate in healthy volunteers. Pharm Res, 18:1029-34.
56. Zobrist RH, Quan D, Thomas HM, et al. 2003. Pharmacokinetics and metabolism of transdermal oxybutynin: In vitro and in vivo performance of a novel delivery system. Pharm Res, 20:103-9.